SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today the addition of Julia P. Gregory to the company’s Board of Directors.
According to William Greene, M.D., Chief Executive Officer, “Julia adds to the Board a uniquely rich background in the strategic financing, planning, partnering, and growth of both public and private biotech companies. With the recent presentation of Iconic’s Phase2a EMERGE key findings in wet Age-related Macular Degeneration, this is an opportune time to add her expertise to our already stellar Board of business and scientific advisors. The EMERGE data demonstrates that our lead candidate, ICON-1, has disease-modifying activity and the potential to directly address the limitations of currently approved therapies.”
“It is with great enthusiasm that I join Bill and the other members of the Board to work with Iconic’s world class scientists and drug developers on these transformative therapies,” commented Ms. Gregory. “I am excited about the opportunity to work with Iconic as the company advances its important, innovative therapeutics for patients in need.”
Julia P. Gregory is a seasoned biotechnology executive with CEO, CFO, Board and investment banking skills. Most recently, she was Chief Executive Officer and Board member of ContraFect Corporation, a public biotechnology company developing innovative anti-infectives. Ms. Gregory has a proven track record of successfully growing, capitalizing, and positioning private and public biotechnology companies. As a biotechnology executive, she has raised more than $1.5 billion across all types of business cycles and structured creative strategic alliances and transactions with pharmaceutical companies including GlaxoSmithKline, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd., Genentech, Inc. (now Roche), and Human Genome Sciences (now GSK).
Age-related Macular Degeneration is the leading cause of blindness in the U.S. and other industrialized countries, affecting up to 200 million people worldwide. The ultimate goal of AMD treatment is to preserve vision and prevent blindness. For over a decade, anti-VEGF agents have been the standard of care, providing good initial responses with rapid reduction of retinal thickness and, in up to 40% of patients, gains in vision. However, treatment with anti-VEGF agents alone may not provide durable outcomes. For many patients, vision gains do not appear to be sustainable over a period of years and thus may not prevent progression to blindness in the long run. There is an unmet need for an agent that can modify the underlying progression of the disease process itself.
About Iconic Therapeutics
Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. The company is investigating the ICON family of proteins in cancer and has initiated a research program in solid tumors. Please visit www.iconictherapeutics.com for additional information.